Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTLL7L74)

DOT Name	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1)
Synonyms	Transducin beta chain 1
Gene Name	GNB1
Related Disease	Intellectual disability, autosomal dominant 42 ( ) Advanced cancer ( ) Anxiety disorder ( ) Depression ( ) Intellectual disability ( ) Neoplasm ( ) Neurodevelopmental disorder ( ) Pathologic nystagmus ( ) Schizophrenia ( ) West syndrome ( ) Cone-rod dystrophy 2 ( ) leukaemia ( ) Leukemia ( ) Gnathodiaphyseal dysplasia ( ) Breast cancer ( ) Breast carcinoma ( ) Cutaneous mastocytosis ( )
UniProt ID	GBB1_HUMAN
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
PDB ID	4KFM ; 4PNK ; 5HE0 ; 5HE1 ; 5HE2 ; 5HE3 ; 5UKK ; 5UKL ; 5UKM ; 5UZ7 ; 6B3J ; 6CRK ; 6D9H ; 6DDE ; 6DDF ; 6E3Y ; 6EG8 ; 6G79 ; 6GDG ; 6KPF ; 6KPG ; 6LFM ; 6LFO ; 6LI3 ; 6LMK ; 6LML ; 6M1H ; 6M1I ; 6M8S ; 6N4B ; 6NI3 ; 6NIY ; 6OIJ ; 6OIK ; 6OMM ; 6ORV ; 6OS9 ; 6OSA ; 6OT0 ; 6P9X ; 6P9Y ; 6PB0 ; 6PB1 ; 6PT0 ; 6UUN ; 6UUS ; 6UVA ; 6VCB ; 6VMS ; 6VN7 ; 6WHA ; 6WHC ; 6WI9 ; 6WPW ; 6WZG ; 6X18 ; 6X19 ; 6X1A ; 6XBJ ; 6XBK ; 6XBL ; 6XBM ; 6XOX ; 7AUE ; 7BB6 ; 7BB7 ; 7C2E ; 7CFM ; 7CFN ; 7CKW ; 7CKX ; 7CKY ; 7CKZ ; 7CMU ; 7CMV ; 7CRH ; 7CX2 ; 7CX3 ; 7CX4 ; 7D76 ; 7D77 ; 7D7M ; 7DB6 ; 7DFL ; 7E2X ; 7E2Y ; 7E2Z ; 7E32 ; 7E33 ; 7E9G ; 7E9H ; 7EB2 ; 7EJ0 ; 7EJ8 ; 7EJA ; 7EJK ; 7EJX ; 7EO2 ; 7EO4 ; 7EPT ; 7EUO ; 7EVW ; 7EVY ; 7EVZ ; 7EW0 ; 7EW1 ; 7EW2 ; 7EW3 ; 7EW4 ; 7EW7 ; 7EXD ; 7EZH ; 7EZK ; 7EZM ; 7F0T ; 7F1O ; 7F1Q ; 7F1R ; 7F1S ; 7F1Z ; 7F23 ; 7F24 ; 7F4D ; 7F4F ; 7F4H ; 7F4I ; 7F53 ; 7F54 ; 7F55 ; 7F58 ; 7F6G ; 7F6H ; 7F6I ; 7F8V ; 7F8W ; 7F9Y ; 7F9Z ; 7JHJ ; 7JOZ ; 7JV5 ; 7JVP ; 7JVQ ; 7JVR ; 7K7L ; 7K7Z ; 7KH0 ; 7KI0 ; 7KI1 ; 7L0P ; 7L0Q ; 7L0R ; 7L0S ; 7L1U ; 7L1V ; 7LCI ; 7LD3 ; 7LD4 ; 7LLL ; 7LLY ; 7MTS ; 7NA7 ; 7NA8 ; 7P00 ; 7P02 ; 7QVM ; 7RA3 ; 7RAN ; 7RBT ; 7RG9 ; 7RGP ; 7RKF ; 7RKM ; 7RKN ; 7RKX ; 7RKY ; 7RMG ; 7RMH ; 7RMI ; 7RTB ; 7RYC ; 7S1M ; 7S3I ; 7S8L ; 7S8M ; 7S8N ; 7S8O ; 7S8P ; 7SBF ; 7SCG ; 7SF7 ; 7SF8 ; 7SR8 ; 7SRR ; 7T10 ; 7T11 ; 7T2G ; 7T2H ; 7T6B ; 7T8X ; 7T90 ; 7T94 ; 7T96 ; 7T9I ; 7T9N ; 7TMW ; 7TRK ; 7TRP ; 7TRQ ; 7TRS ; 7TUZ ; 7TYF ; 7TYH ; 7TYI ; 7TYL ; 7TYN ; 7TYO ; 7TYW ; 7TYX ; 7TYY ; 7TZF ; 7U2K ; 7U2L ; 7UM5 ; 7UM6 ; 7UM7 ; 7UTZ ; 7V68 ; 7V69 ; 7V6A ; 7VDH ; 7VDL ; 7VDM ; 7VFX ; 7VGX ; 7VIE ; 7VIF ; 7VIG ; 7VIH ; 7VKT ; 7VL8 ; 7VL9 ; 7VLA ; 7VUG ; 7VUH ; 7VUI ; 7VUJ ; 7VUY ; 7VUZ ; 7VV3 ; 7VV5 ; 7W0L ; 7W0M ; 7W0N ; 7W0O ; 7W0P ; 7W2Z ; 7W3Z ; 7W40 ; 7W53 ; 7W55 ; 7W56 ; 7W57 ; 7W6P ; 7W7E ; 7WCM ; 7WCN ; 7WF7 ; 7WJ5 ; 7WKD ; 7WU2 ; 7WU3 ; 7WU4 ; 7WU5 ; 7WU9 ; 7WUI ; 7WUJ ; 7WUQ ; 7WV9 ; 7WVU ; 7WVV ; 7WVW ; 7WVX ; 7WVY ; 7WXU ; 7WXW ; 7WY0 ; 7WY5 ; 7WY8 ; 7WYB ; 7WZ4 ; 7WZ7 ; 7X10 ; 7X2C ; 7X2D ; 7X2F ; 7X2V ; 7X5H ; 7X9A ; 7X9B ; 7X9C ; 7X9Y ; 7XA3 ; 7XBD ; 7XBW ; 7XBX ; 7XJJ ; 7XJK ; 7XJL ; 7XK2 ; 7XK8 ; 7XKD ; 7XKE ; 7XKF ; 7XMR ; 7XMS ; 7XMT ; 7XOU ; 7XOV ; 7XOW ; 7XP4 ; 7XP5 ; 7XP6 ; 7XT8 ; 7XT9 ; 7XTA ; 7XTB ; 7XTC ; 7XTQ ; 7XV3 ; 7XW5 ; 7XW6 ; 7XXH ; 7XXI ; 7XY6 ; 7XY7 ; 7XZ5 ; 7XZ6 ; 7Y1F ; 7Y24 ; 7Y26 ; 7Y27 ; 7Y3G ; 7Y64 ; 7Y65 ; 7Y66 ; 7Y67 ; 7Y89 ; 7YAC ; 7YAE ; 7YDH ; 7YDJ ; 7YDM ; 7YDP ; 7YFC ; 7YFD ; 7YK6 ; 7YK7 ; 7YKD ; 7YON ; 7YOO ; 7YP7 ; 7YS6 ; 8DDW ; 8DDX ; 8DPF ; 8DPG ; 8DPH ; 8DPI ; 8DWC ; 8DWG ; 8DWH ; 8DZP ; 8DZQ ; 8DZR ; 8DZS ; 8E3X ; 8E3Y ; 8E3Z ; 8E9W ; 8E9X ; 8E9Y ; 8E9Z ; 8EIT ; 8EJC ; 8EJK ; 8EMW ; 8EMX ; 8F0J ; 8F0K ; 8F2A ; 8F2B ; 8F76 ; 8FEG ; 8FLQ ; 8FLR ; 8FLS ; 8FLT ; 8FLU ; 8FMZ ; 8FN0 ; 8FN1 ; 8FU6 ; 8FX5 ; 8G05 ; 8G2Y ; 8G59 ; 8G94 ; 8GHV ; 8GUQ ; 8GUR ; 8GUS ; 8GUT ; 8GY7 ; 8H0P ; 8H0Q ; 8H2G ; 8H4I ; 8H4K ; 8H4L ; 8H8J ; 8HBD ; 8HCQ ; 8HCX ; 8HDO ; 8HDP ; 8HIX ; 8HJ0 ; 8HJ2 ; 8HJ5 ; 8HMP ; 8HMV ; 8HNK ; 8HNL ; 8HNM ; 8HPT ; 8HQC ; 8HQE ; 8HQM ; 8HQN ; 8HS3 ; 8HSC ; 8HVI ; 8I2G ; 8I95 ; 8I97 ; 8I9A ; 8I9L ; 8I9S ; 8IA2 ; 8IA7 ; 8IA8 ; 8IBU ; 8IBV ; 8IC0 ; 8ID3 ; 8ID4 ; 8ID6 ; 8ID8 ; 8ID9 ; 8INR ; 8IOC ; 8IOD ; 8IRR ; 8IRS ; 8IRT ; 8IRU ; 8IRV ; 8ITF ; 8IUK ; 8IUL ; 8IUM ; 8IW1 ; 8IW4 ; 8IW7 ; 8IW9 ; 8IYS ; 8IZB ; 8J18 ; 8J19 ; 8J1A ; 8J6D ; 8J6P ; 8J6Q ; 8J6R ; 8JD3 ; 8JD5 ; 8JD6 ; 8JHY ; 8JII ; 8JIL ; 8JIM ; 8JKB ; 8JLJ ; 8JLK ; 8JLN ; 8JLO ; 8JLP ; 8JLQ ; 8JLR ; 8JLZ ; 8JR9 ; 8JSO ; 8JSP ; 8JZ7 ; 8JZZ ; 8K2X ; 8K4N ; 8KGK ; 8KH4 ; 8KH5 ; 8PM2 ; 8SAI ; 8SG1 ; 8TB0 ; 8THK ; 8THL ; 8U26 ; 8U7Z ; 8U81 ; 8U82 ; 8U83 ; 8U84 ; 8UQO ; 8W87 ; 8W88 ; 8W89 ; 8W8A ; 8W8B ; 8WPU ; 8WRB
Pfam ID	PF00400
Sequence	MSELDQLRQEAEQLKNQIRDARKACADATLSQITNNIDPVGRIQMRTRRTLRGHLAKIYA MHWGTDSRLLVSASQDGKLIIWDSYTTNKVHAIPLRSSWVMTCAYAPSGNYVACGGLDNI CSIYNLKTREGNVRVSRELAGHTGYLSCCRFLDDNQIVTSSGDTTCALWDIETGQQTTTF TGHTGDVMSLSLAPDTRLFVSGACDASAKLWDVREGMCRQTFTGHESDINAICFFPNGNA FATGSDDATCRLFDLRADQELMTYSHDNIICGITSVSFSKSGRLLLAGYDDFNCNVWDAL KADRAGVLAGHDNRVSCLGVTDDGMAVATGSWDSFLKIWN
Function	Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction.
KEGG Pathway	Ras sig.ling pathway (hsa04014 ) Chemokine sig.ling pathway (hsa04062 ) PI3K-Akt sig.ling pathway (hsa04151 ) Apelin sig.ling pathway (hsa04371 ) Circadian entrainment (hsa04713 ) Retrograde endocan.binoid sig.ling (hsa04723 ) Glutamatergic sy.pse (hsa04724 ) Cholinergic sy.pse (hsa04725 ) Serotonergic sy.pse (hsa04726 ) GABAergic sy.pse (hsa04727 ) Dopaminergic sy.pse (hsa04728 ) Olfactory transduction (hsa04740 ) Phototransduction (hsa04744 ) Relaxin sig.ling pathway (hsa04926 ) Morphine addiction (hsa05032 ) Alcoholism (hsa05034 ) Human cytomegalovirus infection (hsa05163 ) Kaposi sarcoma-associated herpesvirus infection (hsa05167 ) Human immunodeficiency virus 1 infection (hsa05170 ) Pathways in cancer (hsa05200 )
Reactome Pathway	Glucagon signaling in metabolic regulation (R-HSA-163359 ) G-protein activation (R-HSA-202040 ) Activation of the phototransduction cascade (R-HSA-2485179 ) Inactivation, recovery and regulation of the phototransduction cascade (R-HSA-2514859 ) Glucagon-like Peptide-1 (GLP1) regulates insulin secretion (R-HSA-381676 ) Olfactory Signaling Pathway (R-HSA-381753 ) Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) (R-HSA-381771 ) ADP signalling through P2Y purinoceptor 12 (R-HSA-392170 ) G beta (R-HSA-392451 ) Prostacyclin signalling through prostacyclin receptor (R-HSA-392851 ) Adrenaline,noradrenaline inhibits insulin secretion (R-HSA-400042 ) Ca2+ pathway (R-HSA-4086398 ) G alpha (q) signalling events (R-HSA-416476 ) G alpha (12/13) signalling events (R-HSA-416482 ) G beta (R-HSA-418217 ) G alpha (s) signalling events (R-HSA-418555 ) ADP signalling through P2Y purinoceptor 1 (R-HSA-418592 ) G alpha (i) signalling events (R-HSA-418594 ) G alpha (z) signalling events (R-HSA-418597 ) Glucagon-type ligand receptors (R-HSA-420092 ) Thromboxane signalling through TP receptor (R-HSA-428930 ) Vasopressin regulates renal water homeostasis via Aquaporins (R-HSA-432040 ) Thrombin signalling through proteinase activated receptors (PARs) (R-HSA-456926 ) Presynaptic function of Kainate receptors (R-HSA-500657 ) Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding (R-HSA-6814122 ) G beta (R-HSA-8964315 ) G beta (R-HSA-8964616 ) Extra-nuclear estrogen signaling (R-HSA-9009391 ) GPER1 signaling (R-HSA-9634597 ) ADORA2B mediated anti-inflammatory cytokines production (R-HSA-9660821 ) Sensory perception of sweet, bitter, and umami (glutamate) taste (R-HSA-9717207 ) Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits (R-HSA-997272 ) Activation of G protein gated Potassium channels (R-HSA-1296041 )

Molecular Interaction Atlas (MIA) of This DOT

17 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance
Intellectual disability, autosomal dominant 42	DISDUGQ8	Definitive	Autosomal dominant	[1]
Advanced cancer	DISAT1Z9	Strong	Genetic Variation	[2]
Anxiety disorder	DISBI2BT	Strong	Biomarker	[3]
Depression	DIS3XJ69	Strong	Biomarker	[3]
Intellectual disability	DISMBNXP	Strong	Biomarker	[4]
Neoplasm	DISZKGEW	Strong	Genetic Variation	[1]
Neurodevelopmental disorder	DIS372XH	Strong	Genetic Variation	[5]
Pathologic nystagmus	DIS1QSPO	Strong	CausalMutation	[1]
Schizophrenia	DISSRV2N	Strong	Altered Expression	[6]
West syndrome	DISLIAU9	Strong	Genetic Variation	[7]
Cone-rod dystrophy 2	DISX2RWY	moderate	Genetic Variation	[8]
leukaemia	DISS7D1V	moderate	Genetic Variation	[9]
Leukemia	DISNAKFL	moderate	Genetic Variation	[9]
Gnathodiaphyseal dysplasia	DISTWRZO	Disputed	Genetic Variation	[4]
Breast cancer	DIS7DPX1	Limited	Biomarker	[10]
Breast carcinoma	DIS2UE88	Limited	Biomarker	[10]
Cutaneous mastocytosis	DISLBZEF	Limited	Genetic Variation	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 Disease(s)

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DOT

This DOT Affected the Drug Response of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Bupivacaine	DM4PRFC	Approved	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1) increases the Therapeutic agent toxicity ADR of Bupivacaine.	[28]
------------------------------------------------------------------------------------

4 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[11]
Arsenic	DMTL2Y1	Approved	Arsenic affects the methylation of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[15]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[22]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the phosphorylation of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[23]
------------------------------------------------------------------------------------

14 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[12]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[13]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[14]
Hydrogen peroxide	DM1NG5W	Approved	Hydrogen peroxide decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[16]
Vorinostat	DMWMPD4	Approved	Vorinostat decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[17]
Rosiglitazone	DMILWZR	Approved	Rosiglitazone affects the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[18]
Testosterone enanthate	DMB6871	Approved	Testosterone enanthate affects the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[19]
Cocaine	DMSOX7I	Approved	Cocaine decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[20]
Resveratrol	DM3RWXL	Phase 3	Resveratrol decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[21]
PMID28870136-Compound-48	DMPIM9L	Patented	PMID28870136-Compound-48 decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[24]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[25]
chloropicrin	DMSGBQA	Investigative	chloropicrin decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[26]
KOJIC ACID	DMP84CS	Investigative	KOJIC ACID increases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[27]
4-hydroxy-2-nonenal	DM2LJFZ	Investigative	4-hydroxy-2-nonenal decreases the expression of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1).	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 14 Drug(s)

References

1	Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. Am J Hum Genet. 2016 May 5;98(5):1001-1010. doi: 10.1016/j.ajhg.2016.03.011. Epub 2016 Apr 21.
2	Mutations in G protein subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.
3	Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains.Psychopharmacology (Berl). 2012 May;221(2):297-315. doi: 10.1007/s00213-011-2574-z. Epub 2011 Nov 24.
4	Novel GNB1 mutations disrupt assembly and function of G protein heterotrimers and cause global developmental delay in humans.Hum Mol Genet. 2017 Mar 15;26(6):1078-1086. doi: 10.1093/hmg/ddx018.
5	Novel GNB1 de novo mutation in a patient with neurodevelopmental disorder and cutaneous mastocytosis: Clinical report and literature review.Eur J Med Genet. 2018 Mar;61(3):157-160. doi: 10.1016/j.ejmg.2017.11.010. Epub 2017 Nov 23.
6	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia.J Psychiatr Res. 2009 Jul;43(11):978-86. doi: 10.1016/j.jpsychires.2008.11.006. Epub 2008 Dec 24.
7	Phenotype-genotype correlations in patients with GNB1 gene variants, including the first three reported Japanese patients to exhibit spastic diplegia, dyskinetic quadriplegia, and infantile spasms.Brain Dev. 2020 Feb;42(2):199-204. doi: 10.1016/j.braindev.2019.10.006. Epub 2019 Nov 15.
8	Association of the Asn306Ser variant of the SP4 transcription factor and an intronic variant in the beta-subunit of transducin with digenic disease.Mol Vis. 2007 Feb 28;13:287-92.
9	An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.Oncogene. 2017 Oct 26;36(43):5985-5994. doi: 10.1038/onc.2017.210. Epub 2017 Jun 26.
10	Guanine nucleotide binding protein 1: a novel transduction protein with a possible role in human breast cancer.Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):69-73.
11	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
12	Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
13	Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
14	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
15	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
16	Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
17	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
18	Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
19	Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
20	Transcriptional profiling in the human prefrontal cortex: evidence for two activational states associated with cocaine abuse. Pharmacogenomics J. 2003;3(1):27-40.
21	Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
22	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
23	Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
24	Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. Respir Res. 2005 Aug 8;6(1):89. doi: 10.1186/1465-9921-6-89.
25	Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A. Int J Mol Sci. 2022 Oct 1;23(19):11620. doi: 10.3390/ijms231911620.
26	Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
27	Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.
28	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.